MCM
AVIR icon

MAI Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

MAI Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-132
Closed -$711 – 2295
2026
Q1 		$711 Buy
132
+37
+39% +$170 ﹤0.01% 4297
2025
Q4 		$340 Hold
95
– – ﹤0.01% 3935
2025
Q3 		$276 Hold
95
– – ﹤0.01% 3683
2025
Q2 		$342 Hold
95
– – ﹤0.01% 3814
2025
Q1 		$285 Hold
95
– – ﹤0.01% 3288
2024
Q4 		$319 Buy
+95
New +$316 ﹤0.01% 3337

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAI Capital Management's AVIR Position: Q2 2026 in Review

MAI Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 132 shares — an estimated $711 sold.

MAI Capital Management first reported a position in AVIR in Q4 2024 and held it in 6 quarters. The position peaked at $711 in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • MAI Capital Management reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 132 Atea Pharmaceuticals shares in Q2 2026, an estimated $711.
  • MAI Capital Management first reported a position in Atea Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Atea Pharmaceuticals position peaked at $711 in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.